Trial Profile
Randomized phase III study of Lipoplatin + paclitaxel versus cisplatin + paclitaxel as front line treatment of advanced epithelial ovarian cancer (EOC).
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 26 May 2011 New trial record